Humanin belongs to a small, unusual family of peptides called mitochondrial-derived peptides (MDPs), which includes MOTS-c, covered elsewhere on this site. Like MOTS-c, humanin has become a fixture of longevity-marketing content online; the actual research behind it is narrower and more preliminary than that marketing tends to suggest.
What It Is
Humanin is unusual among peptides in where it comes from: it's encoded not by nuclear DNA but by a short open reading frame within the mitochondrial genome, specifically within the region of the 16S rRNA gene. Researchers who study it describe it as an evolutionarily ancient signaling molecule, conserved across many animal species, that appears to let mitochondria communicate stress or damage signals to the rest of the cell and body. It's generally described as neuroprotective and cytoprotective in laboratory research, meaning it appears to help protect nerve cells and cells generally from certain types of damage in experimental settings.
What Animal Research Shows
The preclinical picture is mixed rather than uniformly positive. In C. elegans (roundworms), overexpressing humanin produced a modest but statistically significant lifespan extension, though the effect depended on a specific longevity-related gene pathway (daf-16/FOXO) being intact. In transgenic mice, humanin exposure produced cytoprotection against certain toxins and improved some metabolic markers, but when researchers gave mice humanin starting in midlife, it did not extend their lifespan, even though it improved several individual healthspan markers like metabolic function, tissue fibrosis, and measures of cognitive decline. Separately, naked mole-rats, which are unusually long-lived for their size, maintain stable humanin levels throughout their lives, which researchers see as suggestive rather than conclusive of a protective role.
What Human Evidence Exists
There are no registered human clinical trials of humanin as a therapeutic. What exists instead is observational data: studies have found that children of centenarians tend to have higher circulating humanin levels than people without that family longevity pattern, and that humanin levels tend to be lower in people with Alzheimer's disease compared with unaffected people of similar age. Findings like these are genuinely interesting starting points for research, but they're correlational, not interventional. They can't establish that raising humanin levels in a given person would produce any specific health benefit, and no controlled human trial has tested that question.
Regulatory Status and Safety
Humanin is not FDA-approved for any use and is typically sold, where it's sold at all, as a research-use-only product. Because there's no human trial data, there's no established human dosing, no formal human safety profile, and no long-term safety data of any kind. As with other unregulated research peptides discussed on this site, products marketed as humanin also come from a supply chain with no standardized purity or quality oversight, which is a separate risk layered on top of the compound's own unknowns.
The Bottom Line
Humanin is a scientifically interesting subject of ongoing mitochondrial and aging research, with a genuinely distinctive origin story and some suggestive animal and observational human findings behind it. It is not a proven longevity intervention, has no human clinical trial evidence, and is not an approved or regulated therapeutic. Anyone interested in the biology of aging should treat it as a research topic to follow rather than a product to use, and should raise any specific health or aging-related concerns with a licensed physician.